0.6561

4.75% 0.0177

Seres Therapeutics Inc (MCRB)

Overview News Price History Option Chain Financials Discussions Forecast

Seres Therapeutics Inc stock is traded at $0.6561, with a volume of 234.32K. It is up +4.75% in the last 24 hours and down -19.69% over the past month. Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Previous Close:

$0.6384

Open:

$0.65

24h Volume:

234.32K

Relative Volume:

0.14

Market Cap:

$111.15M

Revenue:

$126.33M

Net Income/Loss:

$-82.68M

P/E Ratio:

-1.0935

EPS:

-0.6

Net Cash Flow:

$-79.98M

1W Performance:

-12.65%

1M Performance:

-19.69%

6M Performance:

-33.08%

1Y Performance:

-12.13%

1-Day Range:

$0.64

$0.6865

1-Week Range:

$0.623

$0.7806

52-Week Range:

$0.54

$1.53

Seres Therapeutics Inc Stock (MCRB) Company Profile

Name

Seres Therapeutics Inc

Sector

Healthcare (1171)

Industry

Biotechnology (679)

Phone

617 945 9626

Address

200 SIDNEY STREET, CAMBRIDGE, MA

Employee

233

Twitter

@SeresTX

Next Earnings Date

2024-10-31

Latest SEC Filings

MCRB's Discussions on Twitter

Compare MCRB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MCRB Seres Therapeutics Inc	0.6565	111.15M	126.33M	-82.68M	-79.98M	-0.60
VRTX Vertex Pharmaceuticals Inc	507.77	130.68B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	679.18	74.97B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.43	36.08B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.07	31.19B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	256.51	27.56B	3.32B	-860.46M	-1.04B	-8.32

Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-24-24	Downgrade	JP Morgan	Neutral → Underweight
Jun-26-23	Resumed	Oppenheimer	Outperform
Apr-21-23	Initiated	JP Morgan	Neutral
Jul-23-21	Downgrade	Goldman	Neutral → Sell
May-18-21	Resumed	Goldman	Neutral
Mar-05-21	Upgrade	Chardan Capital Markets	Neutral → Buy
Sep-18-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-11-20	Reiterated	H.C. Wainwright	Buy
Aug-11-20	Upgrade	Jefferies	Hold → Buy
Apr-30-19	Initiated	Jefferies	Hold
Oct-22-18	Initiated	Chardan Capital Markets	Buy
Oct-13-17	Initiated	Oppenheimer	Outperform
Aug-04-17	Reiterated	H.C. Wainwright	Buy
Feb-01-17	Reiterated	FBR & Co.	Outperform
Aug-12-16	Reiterated	FBR Capital	Outperform
Aug-01-16	Downgrade	BofA/Merrill	Buy → Neutral
Aug-01-16	Reiterated	H.C. Wainwright	Buy
Jul-29-16	Resumed	H.C. Wainwright	Buy
Mar-30-16	Initiated	FBR Capital	Outperform
Mar-03-16	Initiated	Guggenheim	Buy
Jan-25-16	Initiated	H.C. Wainwright	Buy
Oct-22-15	Upgrade	BofA/Merrill	Neutral → Buy
Jul-22-15	Initiated	Canaccord Genuity	Buy
Jul-21-15	Initiated	Goldman	Neutral
Jul-21-15	Initiated	Leerink Partners	Outperform

View All

Seres Therapeutics Inc Stock (MCRB) Latest News

08:12 AM

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey

08:12 AM

03:23 AM

Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks

03:23 AM

03:04 AM